newsfilter
← Latest News
GlobeNewswire·

Trevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual Meeting

NEW HAVEN, Conn., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine ER for the treatment of